Evidence map›Paper›PMID 37456581›Full record

ReviewBioactive materials2023

Mesenchymal stem cell secretome and extracellular vesicles for neurodegenerative diseases: Risk-benefit profile and next steps for the market access.

Lorella Giovannelli, Elia Bari, Claudio Jommi, Fulvio Tartara, Daniele Armocida, Diego Garbossa, Fabio Cofano, Maria Luisa Torre, Lorena Segale

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Bioactive materials, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 77 papers.

0numbers the graph read from it
0cells of the map it votes in
77citing papers in PubMed
13.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

77 citing papers in PubMed, 90 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. TiOBioprocess and biosystems engineering · 2026
    Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. 3D-bioprinted adipose-derived stem cell-secreted GAS6Journal of nanobiotechnology · 2026
    Article
  19. Review
  20. Review

17 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Lorella GiovannelliDepartment of Pharmaceutical Sciences, University of Piemonte Orientale, 28100, Novara, Italy.
Elia BariDepartment of Pharmaceutical Sciences, University of Piemonte Orientale, 28100, Novara, Italy.
Claudio JommiDepartment of Pharmaceutical Sciences, University of Piemonte Orientale, 28100, Novara, Italy.
Fulvio TartaraIRCCS Mondino Foundation, 27100, Pavia, Italy.
Daniele ArmocidaA.U.O, Policlinico Umberto I, Neurosurgery Division, Human Neurosciences Department, Sapienza University, 00135, Roma, Italy.
Diego GarbossaDepartment of Neuroscience Rita Levi Montalcini, Neurosurgery Unit, University of Turin, 10126, Turin, Italy.
Fabio CofanoDepartment of Neuroscience Rita Levi Montalcini, Neurosurgery Unit, University of Turin, 10126, Turin, Italy.
Maria Luisa TorreDepartment of Pharmaceutical Sciences, University of Piemonte Orientale, 28100, Novara, Italy.
Lorena SegaleDepartment of Pharmaceutical Sciences, University of Piemonte Orientale, 28100, Novara, Italy.
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” · ITUniversity of Turin · ITPoliclinico Umberto I · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neurodegenerative diseases represent a growing burden on healthcare systems worldwide. Mesenchymal stem cells (MSCs) have shown promise as a potential therapy due to their neuroregenerative, neuroprotective, and immunomodulatory properties, which are, however, linked to the bioactive substances they release, collectively known as secretome. This paper provides an overview of the most recent research on the safety and efficacy of MSC-derived secretome and extracellular vesicles (EVs) in clinical (if available) and preclinical models of Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, acute ischemic stroke, and spinal cord injury. The article explores the biologically active substances within MSC-secretome/EVs, the mechanisms responsible for the observed therapeutic effects, and the strategies that may be used to optimize MSC-secretome/EVs production based on specific therapeutic needs. The review concludes with a critical discussion of current clinical trials and a perspective on potential future directions in translating MSC-secretome and EVs into the clinic, specifically regarding how to address the challenges associated with their pharmaceutical manufacturing, including scalability, batch-to-batch consistency, adherence to Good Manufacturing Practices (GMP) guidelines, formulation, and storage, along with quality controls, access to the market and relative costs, value for money and impact on total expenditure.

Indexed as

Brain regenerationExosomesMesenchymal stem cellsMicrovesiclesSecretomeSecretome formulation

Identifiers

PMID37456581
PMCPMC10338239
OpenAlexW4382360568

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.